SynthesisInflammopharmacology2026
The effect of pregabalin on pain and function in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnee osteoarthritis (OA) is a prevalent chronic condition characterized by joint pain and functional impairment. While non-steroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of pharmacologic management, a subset of patients may experience persistent symptoms due to central sensitization. Pregabalin, a neuromodulator used in neuropathic pain, has been proposed as an adjunctive treatment for OA, but its efficacy remains unclear.
objectiveTo evaluate the effectiveness and safety of pregabalin in reducing pain and improving function among patients with knee OA through a systematic review and meta-analysis of randomized controlled trials (RCTs).
methodsWe searched PubMed, Embase, Scopus, and Cochrane CENTRAL from inception to June 2025 for RCTs comparing pregabalin (alone or in combination with NSAIDs) versus control (NSAIDs or placebo) in knee OA patients. Primary outcomes were pain (Visual Analog Scale, VAS) and function (Western Ontario and McMaster Universities Osteoarthritis Index, WOMAC). A random-effects model was used to calculate pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane RoB 2.0 tool.
resultsThree RCTs comprising four treatment arms with 214 patients were included. Pregabalin, when combined with NSAIDs, resulted in significant functional improvement (WMD: - 10.55; 95% CI: - 19.47 to - 1.63) and a non-significant trend toward pain reduction (WMD: - 0.63; 95% CI: - 1.44 to 0.18). Pregabalin monotherapy was less effective than combination therapy. Moderate to high heterogeneity was observed. Adverse events, primarily dizziness and somnolence, were mild and did not lead to discontinuation.
conclusionPregabalin may enhance functional outcomes and contribute to pain relief when used as adjunctive therapy with NSAIDs in knee OA patients. Its benefit as monotherapy remains limited. While pregabalin was generally well-tolerated, larger, high-quality trials with longer follow-up are needed to confirm its role and long-term safety.
Indexed as
Identifiers
42481863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.